Recent news coverage from primary business news sources does not mention Nutra Pharma or its products, indicating limited current public visibility.

• Recent business news headlines focus on agricultural commodities, stock market movements, and other companies unrelated to Nutra Pharma [N1][N2][N3][N4][N5][N6][N7][N8].

Nutra Pharma has developed a portfolio of OTC pain relief products with a unique active ingredient, Asian cobra venom, supported by clinical studies and FDA registration as homeopathic drugs. The company’s in-house manufacturing capabilities provide operational control and potential margin benefits. Its drug candidates targeting neurological and viral diseases have orphan designation and may benefit from regulatory incentives. International expansion efforts and private label manufacturing add potential revenue streams. The company’s commitment to regulatory compliance and product innovation supports its business continuity.

Nutra Pharma faces significant liquidity challenges as indicated by its low current and cash ratios and net losses reported in recent filings. The company’s products are homeopathic and face regulatory scrutiny, including past FDA warning letters. Marketing efforts have been limited by funding constraints, and international regulatory approvals have been delayed. The competitive pharmaceutical and pain relief markets may limit growth opportunities. The company’s drug candidates remain subject to FDA approval, which involves significant risk and uncertainty. Overall, financial and operational risks may impact business sustainability.

Nutra Pharma's moat is based on its proprietary use of Asian cobra venom as an active pharmaceutical ingredient in its OTC pain relief products, supported by a US monograph under the Homeopathic Pharmacopoeia and FDA registration. The company’s in-house GMP-certified manufacturing facility provides control over production costs and product quality. Its portfolio includes unique homeopathic formulations for human and animal pain relief, with some clinical evidence supporting efficacy and safety. The orphan drug designation for one of its drug candidates may provide regulatory advantages. However, the company operates in a competitive pharmaceutical and homeopathic market with regulatory scrutiny and funding challenges, which may limit moat strength.

• Liquidity Risk: The company’s current ratio of 0.02 and cash ratio of 0 as of June 30, 2026, indicate significant liquidity constraints that may affect its ability to meet short-term obligations and fund operations [S2].
• Regulatory Risk: Nutra Pharma’s products are homeopathic and subject to FDA regulation; past FDA warning letters highlight risks related to marketing claims and compliance [S1].
• Funding Risk: Limited funding has delayed clinical studies and international regulatory approvals, constraining marketing and product development efforts [S1].
• Market Competition: The pharmaceutical and OTC pain relief markets are competitive, with many alternatives to Nutra Pharma’s products, potentially limiting market share and growth [S1].
• Product Approval Risk: Drug candidates for neurological and viral diseases are subject to FDA approval processes that involve significant uncertainty and risk [S1].

• Nutra Pharma is a biopharmaceutical company incorporated in California in 2000, focusing on drugs for autoimmune disorders, viral diseases, and pain [S1].
• The company develops, licenses, and commercializes pharmaceutical products and homeopathic drugs for pain, neurological disorders, cancer, autoimmune and infectious diseases [S1].
• Nutra Pharma markets several over-the-counter (OTC) pain relief products including Nyloxin, Nyloxin Extra Strength, Pet Pain-Away (for cats and dogs), Equine Pain-Away (for horses), and Luxury Feet (for foot pain from high heels) [S1].
• Nyloxin products use Asian cobra venom as the active pharmaceutical ingredient (API), which has a US monograph under the Homeopathic Pharmacopoeia of the United States (HPUS) and FDA registration as homeopathic drugs [S1].
• Nyloxin and Nyloxin Extra Strength are available as topical gels and oral sprays for moderate to severe chronic pain, with a safety profile supported by clinical studies dating back to the 1930s [S1].
• The company has developed two drug candidates, RPI-78M for neurological and autoimmune diseases and RPI-MN for viral diseases including HIV/AIDS and Herpes; these are subject to FDA approval [S1].
• Nutra Pharma completed bringing all manufacturing in-house by March 2022, operating a GMP-certified facility with ISO Class 5 clean room certification, enabling reduced costs and faster product upgrades [S1].
• The company manufactures its products including Nyloxin and Pet Pain-Away, and has acted as a contract manufacturer for third parties, though some contract manufacturing was transitioned to related parties in 2025 [S1].
• Nutra Pharma has faced FDA regulatory scrutiny, including a 2019 warning letter regarding marketing claims for Nyloxin products, to which it responded and made changes to comply [S1].
• The company pursues international registrations and distribution partnerships, including efforts in India and Canada, with some delays due to funding and COVID-19 [S1].
• Financial snapshot as of 2026-06-30 shows cash and equivalents of $12,181,000 (as of 2025-12-31), short-term investments of $17,600,000, current assets of $463,119,000, and current liabilities of $21,696,808,000, resulting in a current ratio of 0.02 and cash ratio of 0, indicating liquidity challenges [S2].
• Net income for the six months ended 2026-06-30 was a loss of $3,948,772, with basic and diluted EPS of $0 [S2].
• The company’s operations have been ongoing since 2003, with a focus on marketing and distribution of its OTC products domestically and internationally [S1].
• Nutra Pharma’s products are sold online (including Amazon and Walmart Marketplace), in physician offices, clinics, and small-chain pharmacies [S1].
• The company’s business plan includes continuing marketing and distribution of its branded products and pursuing clinical studies comparing Nyloxin Extra Strength to prescription pain relievers, subject to funding availability [S1].
• Recent news items in the primary business news sources do not mention Nutra Pharma or its products, indicating limited recent public coverage [N1][N2][N3][N4][N5][N6][N7][N8].